Shipped monthly
Applying those same ingredients to the skin introduces an absorption barrier that has not been validated for this purpose (7,9,10), and no Australia regulator has approved any over-the-counter GLP-1 patch for safety or efficacy
A notable proportion of patients achieved MASH resolution without worsening fibrosis Phase 3 program : Multiple ongoing trials evaluating survodutide in obesity (SYNCHRONIZE program) and MASH, with topline results expected 2025-2026 Mechanism studies : Preclinical data confirming glucagon-mediated hepatic fat oxidation, increased energy expenditure, and weight-independent improvements in liver histology Developer : Boehringer Ingelheim, which has positioned survodutide as a potential first-in-class treatment for MASH, a disease with limited approved therapies Tirzepatide Research# Tirzepatide has one of the most extensive clinical evidence bases of any metabolic peptide: SURPASS program (Type 2 diabetes): Five Phase 3 trials demonstrating superior HbA1c reduction versus insulin glargine (SURPASS-1), semaglutide 1 mg (SURPASS-2), insulin degludec (SURPASS-3), and insulin glargine + lispro (SURPASS-4)
TEST RESULTS What our customers say IGF-1 LR3 1mg arrived with clear documentation, intact packaging and a batch-specific COA that made internal receipt checks straightforward
The weekly dosing schedule, combined with the body rapid clearance of water-soluble vitamins, provides a substantial safety margin
Diabetes Care 27:1335-1342, 2004
